A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs

Many oral anticancer drugs are metabolized by CYP3A. Clinical drug-drug interaction (DDI) studies often only examine the effect of strong CYP3A inhibitors and inducers. The effect of moderate or weak inhibitors or inducers can be examined using physiologically based pharmacokinetic simulations, but...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Laura Molenaar-Kuijsten, Dorieke E. M. Van Balen, Jos H. Beijnen, Neeltje Steeghs, Alwin D. R. Huitema
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2021-08-01
coleção:	Frontiers in Pharmacology
Assuntos:	drug interaction cytochrome P450 enzyme CYP3A inhibitor CYP3A inducer cancer kinase inhibitor
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2021.670862/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!